Regeneron’s Investigational COVID-19 Antibody Added to UK Recovery Trial

Regeneron Pharmaceuticals’ investigational COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial aimed at finding effective COVID-19 treatments.

The phase 3 trial will evaluate the effects of REGN-COV2 in addition to standard of care compared to standard of care alone in 4,000 hospitalized COVID-19 patients. The antibody cocktail is the first specifically designed COVID-19 treatment to be evaluated in the trial.

REGN-COV2 is currently being studied in two phase 2/3 trials as COVID-19 treatments and in a separate phase 3 trial for the prevention of COVID-19.